PIPE-791's Phase 2 IPF readout in 2027 will determine whether LPA1 antagonism can deliver measurable FVC preservation in a field where two approved antifibrotics set a high bar

Bull

A positive outcome would show statistically significant preservation of FVC (mL) at week 26 versus placebo, ideally with an effect size comparable to or exceeding the ~100–135 mL annual FVC decline attenuation seen with approved antifibrotics nintedanib and pirfenidone. Differentiation on tolerability — given the GI and hepatic side-effect burden of existing agents — or a signal suggesting additive benefit in patients already on background antifibrotic therapy would further strengthen the case for a pivotal program and meaningfully expand the commercial opportunity.

Bear

The most likely failure mode is a numerically positive but statistically underpowered or clinically modest FVC signal that does not clear the bar set by approved standards of care, leaving the LPA1 mechanism unvalidated in IPF. Secondary risks include high dropout or background antifibrotic use confounding the treatment effect, or a safety signal (e.g., hepatotoxicity or cardiovascular findings) that complicates the benefit-risk profile and limits dose optimization in a subsequent pivotal trial.